Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.61 |
| ▸ | BRAF | P15056 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 6/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257507 | 0.88 | FLT3 (0.57) | RETBRAFSLC2A1FLT3KDR | |
| SCHEMBL1256177 | 0.88 | SLC2A1 (0.62) | RETSLC2A1FLT3KDRAURKA | |
| SCHEMBL4409304 | 0.87 | RET (0.55) | RETBRAFNPC1RAB9ASLC2A1 | |
| SCHEMBL1255112 | 0.85 | NPC1 (0.55) | RETNPC1RAB9AFLT3KDR | |
| SCHEMBL1256284 | 0.82 | EGFR (0.56) | RETBRAFSLC2A1FLT3KDR | |
| SCHEMBL1255154 | 0.82 | SLC2A1 (0.56) | RETSLC2A1FLT3KDRAURKA | |
| SCHEMBL1256857 | 0.80 | FLT3 (0.54) | RETNPC1RAB9ASLC2A1FLT3 | |
| SCHEMBL1257973 | 0.79 | FLT3 (0.66) | RETSLC2A1FLT3KDRAURKA | |
| SCHEMBL23803456 | 0.78 | RET (0.78) | RETFLT3KDRAURKACSF1R | |
| SCHEMBL4716379 | 0.77 | SLC2A1 (0.55) | RETBRAFSLC2A1FLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | RET 16/4885BRAF 75/4885NPC1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.